Wuhan YZY Biopharma Co., Ltd.
Quick facts
| Founded | 2010 |
|---|
Phase 3 pipeline
- M701 · Oncology
M701 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses.
Phase 2 pipeline
- paracentesis · Other
Phase 1 pipeline
- Chort 1 of M802
- Chort 2 of M802
- Cisplatin pleural infusion
- Cohort 1 of M701
- Cohort 1 of Y101D
- Cohort 3 of M802
- M701 pleural infusion
- Y101D
- Y150
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: